Overview
Pharmaceutical-grade solubilizer excipients are specialized additives designed to increase the solubility of hydrophobic active pharmaceutical ingredients (APIs) in aqueous media. These compounds play a critical role in modern drug formulation, particularly for Biopharmaceutics Classification System (BCS) Class II and IV drugs where poor solubility limits bioavailability. The global market for solubility enhancement excipients is projected to grow at 6.8% CAGR through 2030, driven by increasing development of poorly soluble new chemical entities. Regulatory bodies including the FDA and EMA strictly govern their use, requiring compliance with pharmacopeial standards (USP/NF, Ph. Eur.). Common categories include non-ionic surfactants (e.g., polysorbates), amphiphilic polymers (e.g., PEGs), and cyclic oligosaccharides (e.g., cyclodextrins). Selection depends on API characteristics, route of administration, and desired release profile.
Physical and Chemical Properties
Solubilizers exhibit distinct physicochemical properties tailored for pharmaceutical applications. Surfactant-types like polysorbate 80 possess hydrophilic-lipophilic balance (HLB) values typically >12, enabling micelle formation at critical micelle concentrations (CMC) ranging from 0.001-0.1 mM. Cyclodextrins form inclusion complexes with APIs through hydrophobic cavity interactions, with binding constants (K1:1) varying from 10² to 10⁴ M⁻¹ depending on molecular fit. Thermal stability varies significantly - PEGs remain stable up to 200°C while some solubilizers like vitamin E TPGS degrade above 150°C. pH tolerance is formulation-critical, with most excipients stable in pH 3-9 ranges. Rheological properties are particularly important for injectables, where viscosity should ideally remain <50 cP at administration temperature.
Main Applications
In oral solid dosage forms, solubilizers are commonly used in concentrations of 5-20% w/w to enhance dissolution rates. For poorly soluble oncology drugs like paclitaxel, Cremophor EL (polyoxyl 35 castor oil) enables IV administration at concentrations up to 6 mg/mL. Self-emulsifying drug delivery systems (SEDDS) incorporate solubilizers at 30-60% of pre-concentrate formulations. Recent advances include their use in amorphous solid dispersions (ASDs) where they inhibit API recrystallization, maintaining supersaturation. In biologics, polysorbate 20/80 prevent protein aggregation at 0.01-0.1% concentrations. Ophthalmic formulations utilize solubilizers like HPβCD at 5-15% to improve corneal penetration while maintaining ocular tolerance.
Safety and Storage
Most pharmaceutical solubilizers require strict storage protocols. Polysorbates are prone to oxidative degradation and often contain antioxidants like BHT (0.1-0.5%). Multi-dose liquid formulations using solubilizers may require nitrogen blanket protection. Cyclodextrins should be stored at <25°C/60% RH to prevent clumping and moisture absorption. Safety assessments must include hemolytic potential (particularly for parenteral use), with acceptable thresholds typically <10% hemolysis at working concentrations. Residual solvents should comply with ICH Q3C guidelines. For temperature-sensitive biologics, the impact of solubilizers on cold chain requirements must be evaluated - some may lower freezing points or prevent ice crystal formation.
B2B Procurement Guide
When procuring pharmaceutical-grade solubilizers, buyers should prioritize vendors with: 1) Current GMP certification for excipient manufacturing, 2) Type IV Drug Master Files (DMFs) or CEP certifications, 3) Full analytical method validation reports. Minimum order quantities (MOQs) typically range from 25kg for standard grades to 1kg for high-purity variants. Technical specifications should include: peroxide value (<10 meq/kg for polysorbates), residual solvent levels (<5000 ppm), microbial limits (<100 CFU/g), and endotoxin levels (<5 EU/mg for injectables). For novel formulations, consider suppliers offering application support with solubility parameter (δ) matching services and compatibility studies. Lead times vary from 2-6 weeks for standard items to 12+ weeks for custom modifications.
Related Manufacturers
- 主营：[]
- 主营：海藻糖、柠檬酸、黄原胶、药用泊洛沙姆、氯化钙、薄荷脑、泊洛沙姆、聚乙烯醇PVA、聚山梨酯、碳酸氢钠、注射蛋黄卵磷脂、注射大豆油、甘油、倍他环糊精、海藻酸钠、聚丙烯酸钠、酒石酸、丙二醇、聚乙二醇、HS15、聚氧乙烯40氢化蓖麻油、山嵛酸甘油酯、羟丙甲纤维素、羟苯甲酯钠
- 主营：苯甲醇、三乙醇胺、甜菊糖苷、注射级海藻糖、注射级甘露醇、注射级木糖醇、注射级甘油、牛磺酸、醋酸钠、木糖醇、黄原胶、甘露醇、大豆油、薄荷脑、二甲硅油、卡波姆、枸橼酸、磷酸氢二钠、磷酸氢二钾、明胶、十六醇、十八醇、聚维酮k30
- 主营：甘油、丙二醇、聚山梨酯80、增溶剂、二甲硅油、二甲基亚砜、苯甲酸苄酯、苯甲醇、泊洛沙姆、聚丙烯酸钠、海藻糖、大豆磷脂、黄原胶、羧甲基纤维素钠、依地酸二钠、海藻酸钠、醋酸氯己定、葡萄糖酸氯己定、聚乙烯醇、聚维酮k30、交联聚维酮、交联羧甲基纤维素钠、RH40
- 主营：硬脂酸镁、泊洛沙姆188、泊洛沙姆407、药用聚乙二醇、聚乙二醇—15羟基硬脂酸酯、巴斯夫进口蓖麻油聚烃氧酯EL35、巴斯夫聚氧乙烯氢化蓖麻油RH40、巴斯夫进口Soluplus、微晶纤维素、聚维酮k30、聚维酮k90、羧甲淀粉钠、低取代羟丙纤维素、羟丙纤维素、羟丙甲纤维素、乳糖、麦芽糊精、交联聚维酮、交联羧甲纤维素钠、海藻糖、甘羟铝、聚丙烯酸钠、卡波姆、亚什兰进口羟乙基纤维素
- 主营：水杨酸、羧甲基纤维素钠、醋酸氯己定、医药级蛋黄卵磷脂、二甲基亚砜、三乙醇胺、二氧化钛、氧化锌、枸橼酸钠、氯化镁、磺胺嘧啶银、枸橼酸钾、苯甲酸钠
- 主营：聚乙二醇、泊洛沙姆、枝共聚物、增溶剂、微晶纤维素、聚醋酸乙烯酯、羟基硬脂酸酯、聚乙烯己内酰胺
- 主营：药用级蜂蜜、药用级海藻糖、药用级卡波姆、药用级泊洛沙姆、药用级交联羧甲纤维素、药用级三乙醇胺、药用级羟苯甲酯、药用级聚丙烯酸钠、药用级甘羟铝、药用级聚山梨酯80、药用级壳聚糖、药用级甘油、药用级丙二醇、药用级蓖麻油
- 主营：甲基纤维素、卡波姆、聚维酮K30、药用蜂蜜、甘油、丙二醇、月桂氮卓酮、麦芽糖、三氯蔗糖、羟苯乙酯、羟苯丙酯、液状石蜡、固体石蜡、三乙醇胺、依地酸二钠、焦亚硫酸钠、苯扎溴铵、泊洛沙姆188/407、明胶、甜菊糖苷、注射用蔗糖
- 主营：丙二醇、聚乙烯醇、巴斯夫进口泊洛沙姆188、增溶剂、泊洛沙姆407、聚氧乙烯氢化蓖麻油、np700、甘油、乳糖、hs15、二甲基亚砜、聚维酮、凡士林、枸橼酸、磷酸二氢钠、高岭土、海藻糖、滑石粉、黄原胶、聚山梨酯、卡波姆、壳聚糖、明胶、三氯蔗糖、蓖麻油、酒石酸
- 主营：Soluplus、HS15、泊洛沙姆188、增溶剂、RH40、EL35、泊洛沙姆407、海藻糖、甘露醇、大豆磷脂、聚乙烯醇、甘羟铝、聚丙烯酸钠、高岭土、羟苯甲酯、羟苯乙酯、透明质酸钠、氨丁三醇、苯甲酸苄酯、1.3丁二醇、二甲基亚砜、硬脂酸铝、枸橼酸三乙酯、中链甘油三酸酯
- 主营：注射级、基倍他环糊精、倍他环糊精钠
- 主营：甘露醇、糖精钠、水杨酸、药用级聚山梨酯80、樟脑、冰片、薄膜包衣粉、糊精、人工牛黄、醋酸氯己定、碳酸氢钠、氯化铵、二甲基亚砜、黄白凡士林、大豆卵磷脂、蛋黄卵磷脂、黄原胶、聚山梨酯80、葡萄糖、羟苯乙酯、氯化钠、碳酸钙、硫酸镁、升华硫
- 主营：海藻糖、甘油、泊洛沙姆、药用辅料、丙二醇、倍他环糊精、聚山梨酯80、聚乙二醇
- 主营：二氧化硅、微晶纤维素、羟丙甲纤维素、药用级聚维酮、药用级二氧化硅、注射级甘露醇、注射级甘油、注射级丙二醇、注射级磷酸氢二钠、注射级依地酸二钠、注射级苯甲醇、注射级海藻糖、注射级聚乙二醇400、注射级蔗糖、注射级乳糖、注射级大豆油、硬脂酸镁、木糖醇、中链甘油三酸酯、二甲基亚砜、无水碳酸钠、无水磷酸二氢钠
- 主营：药用辅料、二甲硅油、甜菊糖苷